Skip to main content
BioCentury
As published for the week of Monday, April 25, 2016


  • Cover Story: Endangered TIGER?

    Handicapping rociletinib's future in NSCLC

    By Erin McCallister, Senior Editor

    Comments from an FDA panel suggest there may still be a path to market for rociletinib from Clovis Oncology Inc. in NSCLC, albeit a much narrower one. But that depends on the company taking advice from the agency — which briefing documents suggest it has not always done to date.

    Finding a path to market also may depend on modifications to the ongoing TIGER-3 trial, especially if physicians or patients are reluctant to participate given the panel's questions about dosing and toxicity, and the availability of newer agents.

    Full Article

Money Raised in 2016

Last week, the biotech industry raised $255 million, bringing to $10.8 billion the total raised year-to-date. In 2015, a total of $110.6 billion was raised, including $56.6 billion in debt, $29.7 billion in follow-ons, $3.7 billion in PIPEs and other equity, $8.1 billion in IPOs, and $12.5 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.